Voyager Therapeutics (VYGR) AI Stock Analysis

• Market Cap: $180.95M
• Dividend Yield: N/A
• Average Volume (3M): 606.33K
• Price to Earnings (P/E): 5.0
• Beta (1Y): 1.39
• Revenue Growth: -43.75%
• EPS Growth: -8479.41%
• Country: US
• Employees: 172
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -0.53
• Shares Outstanding: 55,336,445
• 10 Day Avg. Volume: 531,302
• 30 Day Avg. Volume: 606,326
• PEG Ratio: 0.07
• Price to Book (P/B): 0.67
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.51
• Enterprise Value/Market Cap: 0.76
• Enterprise Value/Revenue: 0.30
• Enterprise Value/Gross Profit: 4.23
• Enterprise Value/Ebitda: -0.84
• 1Y Price Target: $15.00
• Price Target Upside: 368.75% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

• Rating: 49 Neutral
• Price Target: $3.00 ▼(-6.25%Downside)

The overall score is primarily impacted by the company's financial challenges, including declining revenues and negative profitability. Technical analysis shows some stability, but the negative P/E ratio and lack of dividends limit valuation appeal.

Positive Factors

Analyst Recommendation

Analyst reiterates BUY recommendation, believing shares remain undervalued ahead of internal/external catalysts.

Financial Performance

Voyager has $295M in cash and a projected runway into mid-2027, indicating meaningful potential value creation from clinical advancement, partnering activity, and platform validation.

Pipeline Development

Voyager's tau-targeting Alzheimer's programs and partnered gene therapy pipeline are progressing, with key milestones expected over the next 12-18 months.

Negative Factors

Earnings Miss

Net loss per share was ($0.53) vs consensus of ($0.45).

Stock Performance

The stock has pulled back approximately 43% this year due to macro factors and investor apathy around small/mid-cap biotech.

Voyager Therapeutics Business Overview & Revenue Model

Company Description

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Voyager Therapeutics makes money primarily through strategic collaborations, licensing agreements, and milestone payments related to its gene therapy programs. The company partners with larger pharmaceutical firms to co-develop and commercialize its therapeutic candidates, which enables it to share in the research and development costs while also receiving upfront payment, milestone payments, and potential royalties on sales. Additionally, Voyager may receive government grants or other funding to support its research initiatives. These partnerships and funding sources are critical to advancing its pipeline and generating revenue before its therapies reach commercialization.

Voyager Therapeutics Financial Statement Overview

Summary

Voyager Therapeutics is experiencing financial challenges including declining revenue, negative profitability margins, and cash flow issues despite a strong equity position. The negative net profit and increasing leverage are major concerns.

Income Statement

Voyager Therapeutics has experienced significant revenue volatility, with a notable decline in revenue from 2023 to TTM. The gross profit margin has decreased, and the company is currently operating at a net loss, impacting net profit margins negatively. The EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The company maintains a strong equity position with a high equity ratio, suggesting financial stability. However, the debt-to-equity ratio has increased slightly, indicating a rise in leverage. Return on equity is negative due to net losses, which is a concern for profitability.

Cash Flow

Operating cash flow is negative, reflecting cash burn, but the company has managed to maintain a positive free cash flow growth rate in TTM. The operating cash flow to net income ratio is unfavorable due to negative net income, indicating cash flow challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	80.00M	250.01M	40.91M	37.41M	171.13M
Gross Profit	80.00M	245.57M	34.72M	-36.37M	62.38M
EBITDA	-78.56M	126.45M	-44.65M	-68.45M	31.20M
Net Income	-65.00M	132.33M	-46.41M	-66.03M	36.74M
Balance Sheet
Total Assets	393.05M	351.28M	159.36M	193.85M	261.58M
Cash, Cash Equivalents and Short-Term Investments	266.68M	230.88M	118.85M	132.54M	181.14M
Total Debt	43.73M	20.29M	23.13M	44.18M	47.61M
Total Liabilities	93.29M	114.96M	100.34M	98.80M	107.26M
Stockholders Equity	299.76M	236.32M	59.02M	95.06M	154.32M
Cash Flow
Free Cash Flow	-18.83M	74.66M	-15.00M	-55.13M	-108.81M
Operating Cash Flow	-15.31M	77.92M	-12.51M	-53.52M	-96.72M
Investing Cash Flow	-94.86M	-141.64M	-7.34M	65.91M	113.00M
Financing Cash Flow	114.02M	33.65M	1.11M	612.00K	3.16M

Voyager Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.20
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VYGR, the sentiment is Negative. The current price of 3.2 is below the 20-day moving average (MA) of 3.26, above the 50-day MA of 3.19, and below the 200-day MA of 4.60, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 48.67 is Neutral, neither overbought nor oversold. The STOCH value of 36.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VYGR.

Voyager Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FHTX	57 Neutral	$362.32M	―	322.49%	―	-30.66%	36.48%
Sector *	52 Neutral	$7.58B	0.48	-62.71%	2.36%	15.33%	0.41%
VYGR	49 Neutral	$180.95M	5.05	-27.61%	―	-43.75%	-8479.41%
FDMT	46 Neutral	$214.95M	―	-32.97%	―	―	―
TERN	45 Neutral	$519.66M	―	-32.12%	―	―	10.98%
PRME	43 Neutral	$550.09M	―	-115.21%	―	―	20.58%
ANNX	38 Underperform	$273.19M	―	-66.13%	―	―	43.21%

Voyager Therapeutics Corporate Events

Voyager Therapeutics Approves Stock Plans at Annual Meeting

At the annual meeting held on June 3, 2025, Voyager Therapeutics‘ stockholders approved the 2025 Stock Incentive Plan and the Amended and Restated 2015 Employee Stock Purchase Plan, both previously adopted by the Board of Directors. Additionally, stockholders elected four Class I directors to serve until the 2028 meeting, approved executive compensation, and ratified Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to impact the company’s governance and operational strategies moving forward.

The most recent analyst rating on (VYGR) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Voyager Therapeutics stock, see the VYGR Stock Forecast page.